Adam Feuerstein on Muck Rack

Adam Feuerstein Verified

As seen in:  The Street

Sr. Columnist at TheStreet, aka the Col. Jessup of biotech/drug stocks. Data Are. I curse. Said one analyst: The likes of Adam Feuerstein attack viciously.

Why Acadia Pharma's (ACAD) First Drug Approval Isn't Moving Stock Higher

Why Acadia Pharma's (ACAD) First Drug Approval Isn't Moving Stock Higher
thestreet.com — Acadia Pharmaceuticals secured its first-ever U.S. drug approval on Friday. The drug, Nuplazid, is also the first medicine approved by the U.S. Food and Drug Administration to quell hallucinations and delusions often experienced with people with advanced Parkinson's disease. And yet, investors are shrugging off Acadia's good news.

How Sarepta (SRPT) Can Secure Speedy FDA Drug Approval Despite a Negative Panel Vote

How Sarepta (SRPT) Can Secure Speedy FDA Drug Approval Despite a Negative Panel Vote
thestreet.com — There's a risk to the consensus investor view that the U.S. Food and Drug Administration will reject Sarepta Therapeutics' Duchenne muscular dystrophy drug eteplirsen following Monday's negative advisory panel. Senior FDA officials, most notably Dr. Janet Woodcock, the agency's top drug evaluator, spent a lot of time at Monday's panel making supportive statements about eteplirsen.

Vertex (VRTX) Forecasts Billion-Dollar Sales for Cystic Fibrosis Drug in '16

Vertex (VRTX) Forecasts Billion-Dollar Sales for Cystic Fibrosis Drug in '16
thestreet.com — Vertex Pharmaceuticals on Wednesday tried to soothe investor fears about the commercial ramp of its cystic fibrosis drug franchise by providing Orkambi sales guidance for the first time since the drug launched last summer. The company also raised slightly the sales guidance for its other cystic fibrosis drug Kalydeco.

MannKind (MNKD) and Its CEO Fail Simple Financial Literacy Test

MannKind (MNKD) and Its CEO Fail Simple Financial Literacy Test
thestreet.com — On a conference call Tuesday night, a sell-side analyst asked MannKind CEO Matt Pfeffer how much money was owed to , the company's former marketing partner for the inhaled insulin Afrezza. "We don't owe any money to Sanofi," Pfeffer replied. He rambled for a bit, then added, "other than a piece of debt."

Sarepta Therapeutics (SRPT) FDA Panel Live Blog

Sarepta Therapeutics (SRPT) FDA Panel Live Blog
thestreet.com — Monday is a crucial day for Sarepta Therapeutics . The live blog above is tracking all the action at a U.S. Food and Drug Administration advisory committee meeting, convened to review eteplirsen, Sarepta's experimental drug for the treatment of Duchenne muscular dystrophy.

An Investors' Guide to Sarepta's (SRPT) Eteplirsen FDA Advisory Panel Meeting

An Investors' Guide to Sarepta's (SRPT) Eteplirsen FDA Advisory Panel Meeting
thestreet.com — I've been writing about the biotech industry and biotech investing for 15 years and I've covered U.S. Food and Drug Administration advisory committee meetings for just as long. One of the first FDA meetings I remember writing about involved Idec Pharmaceuticals and its lymphoma drug Zevalin. The date was Sept.

Biotech Stock Mailbag: Is There a Future for Sarepta Therapeutics (SRPT)?

Biotech Stock Mailbag: Is There a Future for Sarepta Therapeutics (SRPT)?
thestreet.com — Questions about Sarepta Therapeutics are dominating my email inbox. This week's Biotech Stock Mailbag focuses on Sarepta's future. Scott D. asks, " What happens to Sarepta Therapeutics if the FDA doesn't approve eteplirsen? I assume the company gets another chance, so what will it need to do the second time?"

FDA Still Negative on Sarepta's (SRPT) DMD Drug, Stock Price Sinks

FDA Still Negative on Sarepta's (SRPT) DMD Drug, Stock Price Sinks
thestreet.com — On Thursday, the U.S. Food and Drug Administration posted an updated but still negative clinical review of eteplirsen, the Duchenne muscular dystrophy drug from Sarepta Therapeutics . Sarepta shares sank 25% to $14.85 in Thursday's pre-market trading session.

Ignoring Criticism, Drug Companies Still Raising Prices, Making More Money

Ignoring Criticism, Drug Companies Still Raising Prices, Making More Money
thestreet.com — Everyone is screaming about drug prices. They're too damn high! Drug spending is going to bankrupt the healthcare system. Raising the price of drugs multiple times per year is unconscionable and unsustainable. How are biotech and pharmaceutical companies responding to all the criticism? They're raising drug prices even more.

Bluebird Bio (BLUE) Gene Therapy Shows Early Promise in Fatal Childhood Brain Disease

Bluebird Bio (BLUE) Gene Therapy Shows Early Promise in Fatal Childhood Brain Disease
thestreet.com — Bluebird Bio is presenting some preliminary clinical trial results Wednesday showing its gene therapy is stabilizing a small number of young boys with an extremely rare, and fatal, inherited neurological disease. The disease is cerebral adrenoleukodystrophy, or CALD. Boys are affected primarily because the disease is inherited through a defective X chromosome carried by the mother.
More Articles →
May 03, 2016

In '08, $PFE gave $MDVN $225m to license dimebon. Now, it might pay A LOT more for the rest. Funny twist.

May 03, 2016

$RLYP - Straight-up debt financing > convertible debt. Not concerned w/ deal structure but it does deflate near-term takeout thesis.

May 03, 2016

RT @michael_gilman: Cleaning up my home office today, found one of my all-time favorite desk cartoons. pic.twitter.com/8FmmE6J0FT

May 03, 2016

Can the “most feared” guy in biotech raise $20K for kids’ cancer research? He’s trying. You want to help? —> httprofile.pmc.org/AF0147M#PMC16

May 03, 2016

Listen to the new Radiohead single for the rest of the day.

May 03, 2016

UCLA (old research partner of $NWBO) is trying to get DCVax/PD1 combo studies started. Investigator-sponsored studies.

May 03, 2016

$MRK $BMY are not working with $NWBO on cancer immunotherapy combination clinical trials, per their respective spokespersons.

May 03, 2016

Why $ACAD First Drug Approval Isn't Moving Stock Higher —> httthestreet.com/story/13555055…ow launch, but will Baker Bros. push for sale?


Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.